Chemomab Therapeutics Ltd DRC (CMMB) - Total Assets
Based on the latest financial reports, Chemomab Therapeutics Ltd DRC (CMMB) holds total assets worth $10.24 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chemomab Therapeutics Ltd DRC - Total Assets Trend (2012–2025)
This chart illustrates how Chemomab Therapeutics Ltd DRC's total assets have evolved over time, based on quarterly financial data. Also see CMMB stock market capitalisation for the company's overall valuation and market capitalisation.
Chemomab Therapeutics Ltd DRC - Asset Composition Analysis
Current Asset Composition (December 2025)
Chemomab Therapeutics Ltd DRC's total assets of $10.24 Million consist of 97.2% current assets and 2.8% non-current assets. Review Chemomab Therapeutics Ltd DRC balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 54.8% |
| Accounts Receivable | $3.06 Million | 22.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Chemomab Therapeutics Ltd DRC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Chemomab Therapeutics Ltd DRC stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chemomab Therapeutics Ltd DRC's current assets represent 97.2% of total assets in 2025, an increase from 96.6% in 2012.
- Cash Position: Cash and equivalents constituted 54.8% of total assets in 2025, down from 60.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 22.2% of total assets.
Chemomab Therapeutics Ltd DRC Competitors by Total Assets
Key competitors of Chemomab Therapeutics Ltd DRC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Chemomab Therapeutics Ltd DRC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.41 | 7.42 | 40.39 |
| Quick Ratio | 6.41 | 7.42 | 57.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.40 Million | $9.18 Million | $64.21 Million |
Chemomab Therapeutics Ltd DRC - Advanced Valuation Insights
This section examines the relationship between Chemomab Therapeutics Ltd DRC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.24 |
| Latest Market Cap to Assets Ratio | 1.30 |
| Asset Growth Rate (YoY) | -18.6% |
| Total Assets | $13.81 Million |
| Market Capitalization | $17.95 Million USD |
Valuation Analysis
Above Book Valuation: The market values Chemomab Therapeutics Ltd DRC's assets above their book value (1.30x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Chemomab Therapeutics Ltd DRC's assets decreased by 18.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Chemomab Therapeutics Ltd DRC (2012–2025)
The table below shows the annual total assets of Chemomab Therapeutics Ltd DRC from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $13.81 Million | -18.58% |
| 2024-12-31 | $16.96 Million | -23.42% |
| 2023-12-31 | $22.15 Million | -48.56% |
| 2022-12-31 | $43.06 Million | -33.08% |
| 2021-12-31 | $64.35 Million | +415.81% |
| 2020-12-31 | $12.48 Million | -36.85% |
| 2019-12-31 | $19.76 Million | +54.81% |
| 2018-12-31 | $12.76 Million | +511.45% |
| 2017-12-31 | $2.09 Million | -63.06% |
| 2016-12-31 | $5.65 Million | +60.70% |
| 2015-12-31 | $3.52 Million | -62.93% |
| 2012-12-31 | $9.48 Million | -- |
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical tri… Read more